222 related articles for article (PubMed ID: 15191331)
1. Contemporary management of prolactinomas.
Liu JK; Couldwell WT
Neurosurg Focus; 2004 Apr; 16(4):E2. PubMed ID: 15191331
[TBL] [Abstract][Full Text] [Related]
2. Disorders of prolactin secretion.
Molitch ME
Endocrinol Metab Clin North Am; 2001 Sep; 30(3):585-610. PubMed ID: 11571932
[TBL] [Abstract][Full Text] [Related]
3. [Prolactinoma].
Glezer A; Bronstein MD
Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
5. Prolactin-secreting tumors: what's new?
Molitch ME
Expert Rev Anticancer Ther; 2006 Sep; 6 Suppl 9():S29-35. PubMed ID: 17004854
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
7. [Prolactinoma].
Krysiak R; Okopień B; Marek B; Szkróbka W
Przegl Lek; 2009; 66(4):198-205. PubMed ID: 19708510
[TBL] [Abstract][Full Text] [Related]
8. Macroprolactinoma: a diagnostic and therapeutic update.
Iglesias P; Díez JJ
QJM; 2013 Jun; 106(6):495-504. PubMed ID: 23329574
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
10. [Prolactin-secreting adenoma].
Brue T; Morange I; Jaquet P
Rev Prat; 1996 Jun; 46(12):1486-9. PubMed ID: 8881162
[TBL] [Abstract][Full Text] [Related]
11. [Some issues in the diagnosis and treatment of hyperprolactinemia].
Jin ZM
Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959
[No Abstract] [Full Text] [Related]
12. Medical management of prolactin-secreting pituitary adenomas.
Molitch ME
Pituitary; 2002; 5(2):55-65. PubMed ID: 12675502
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas in children and adolescents--consequences in adult life.
Duntas LH
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1227-32; discussion 1261-2. PubMed ID: 11964017
[TBL] [Abstract][Full Text] [Related]
14. Update in prolactinomas.
Kars M; Dekkers OM; Pereira AM; Romijn JA
Neth J Med; 2010 Mar; 68(3):104-12. PubMed ID: 20308704
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
16. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
17. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
18. Current management of prolactinomas.
Nomikos P; Buchfelder M; Fahlbusch R
J Neurooncol; 2001 Sep; 54(2):139-50. PubMed ID: 11761431
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of prolactinomas.
Molitch ME
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):143-69, vii. PubMed ID: 10207689
[TBL] [Abstract][Full Text] [Related]
20. Single-centre experience of stereotactic radiosurgery and fractionated stereotactic radiotherapy for prolactinomas with the linear accelerator.
Wilson PJ; Williams JR; Smee RI
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):371-8. PubMed ID: 25410143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
